Astrocytes in Parkinson's Disease: From Role to Possible Intervention

被引:10
|
作者
Wang, Tianyou [1 ]
Sun, Yingqi [2 ]
Dettmer, Ulf [3 ,4 ]
机构
[1] Coll Jean de Brebeuf, 3200 Chemin Cote St Catherine, Montreal, PQ H3T 1C1, Canada
[2] Univ Oxford, Dept Biochem, Oxford OX1 3QU, England
[3] Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA
[4] Harvard Med Sch, Boston, MA 02115 USA
关键词
astrocyte; Parkinson's disease; neuron-astrocyte interactions; glutamate; alpha-synuclein; disease-modifying therapy for PD; BLOOD-BRAIN-BARRIER; VENTRICULAR CEREBROSPINAL-FLUID; ALPHA-SYNUCLEIN; RAT MODEL; GLUTAMATE TRANSPORTER; GROWTH-FACTOR; MICE LACKING; DOUBLE-BLIND; MECHANISMS; CELLS;
D O I
10.3390/cells12192336
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons. While neuronal dysfunction is central to PD, astrocytes also play important roles, both positive and negative, and such roles have not yet been fully explored. This literature review serves to highlight these roles and how the properties of astrocytes can be used to increase neuron survivability. Astrocytes normally have protective functions, such as releasing neurotrophic factors, metabolizing glutamate, transferring healthy mitochondria to neurons, or maintaining the blood-brain barrier. However, in PD, astrocytes can become dysfunctional and contribute to neurotoxicity, e.g., via impaired glutamate metabolism or the release of inflammatory cytokines. Therefore, astrocytes represent a double-edged sword. Restoring healthy astrocyte function and increasing the beneficial effects of astrocytes represents a promising therapeutic approach. Strategies such as promoting neurotrophin release, preventing harmful astrocyte reactivity, or utilizing regional astrocyte diversity may help restore neuroprotection.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Is it possible to differentiate Alzheimer's disease from Parkinson's disease dementia by praxis tests?
    Sanli, Zeynep Selcan
    Evlice, Ahmet
    Binokay, Hulya
    DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, 2023, 36 (04): : 222 - 229
  • [42] Astrocytes in Parkinson's disease: from preclinical assays to in vivo imaging and therapeutic probes
    Zeng, Zhou
    Roussakis, Andreas-Antonios
    Lao-Kaim, Nicholas P.
    Piccini, Paola
    NEUROBIOLOGY OF AGING, 2020, 95 : 264 - 270
  • [43] Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation
    Peter Teismann
    Jörg B. Schulz
    Cell and Tissue Research, 2004, 318 : 149 - 161
  • [44] Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation
    Teismann, P
    Schulz, JB
    CELL AND TISSUE RESEARCH, 2004, 318 (01) : 149 - 161
  • [45] Astrocytes, a Promising Opportunity to Control the Progress of Parkinson's Disease
    Sanchez, Alberto
    Morales, Ingrid
    Rodriguez-Sabate, Clara
    Sole-Sabater, Miguel
    Rodriguez, Manuel
    BIOMEDICINES, 2021, 9 (10)
  • [46] Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
    Miyazaki, Ikuko
    Asanuma, Masato
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (33) : 4936 - 4947
  • [47] Hyposmia: a possible biomarker of Parkinson's disease
    Xiao, Qian
    Chen, Sheng
    Le, Weidong
    NEUROSCIENCE BULLETIN, 2014, 30 (01) : 134 - 140
  • [48] A review of possible therapies for Parkinson's disease
    Chakraborty, Ashok
    Brauer, Sam
    Diwan, Anil
    JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 76 : 1 - 4
  • [49] Hyposmia: a possible biomarker of Parkinson’s disease
    Qian Xiao
    Sheng Chen
    Weidong Le
    Neuroscience Bulletin, 2014, 30 : 134 - 140
  • [50] Hyposmia: a possible biomarker of Parkinson's disease
    Qian Xiao
    Sheng Chen
    Weidong Le
    Neuroscience Bulletin, 2014, 30 (01) : 134 - 140